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Objective. We performed a systematic review of the literature to evaluate the eﬀects of alpha lipoic acid for symptomatic
peripheralneuropathyinpatientswithdiabetesmellitus.Researchdesignandmethods.ThedatabasesMEDLINEandEMBASEwere
searched using the key words “lipoic acid”, “thioctic acid”, “diabet∗”, and the MeSH-terms “thioctic acid” and “diabetes mellitus”.
Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological
quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled
standardized mean diﬀerence estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P =
0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10;
P = 0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P = 0.0001) conﬁrmed the robustness of the overall
result. Conclusions. When given intravenously at a dosage of 600mg/day over a period of 3 weeks, alpha lipoic acid leads to a
signiﬁcant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the signiﬁcant
improvements seen after 3–5 weeks of oral administration at a dosage of >600mg/day are clinically relevant.
1.Introduction
Neuropathy is a microvascular complication of diabetes mel-
litus which leads to considerable morbidity and a decreased
quality of life [1]. Peripheral neuropathy can present as
tingling, burning, pain, cramps, paresthesia, or numbness.
There is overwhelming evidence that the development of
microvascular complications is related to the level of glucose
dysregulationoveralongperiodoftime[2].Hyperglycaemia
induces an increased production of free oxygen radicals
in the mitochondria (oxidative stress), which leads to the
activation of the four known pathways that are responsible
for hyperglycaemic damage: the polyol, hexosamine, protein
kinase C, and AGE pathways [3]. This results in damage of
endothelial and neuronal cells.
Neuropathic pain is diﬃcult to treat, and standard anal-
gesics are usually not eﬀective enough [4]. The medications
whicharecurrentlyusedtotreatneuropathicpaininpatients
with diabetes include mainly antidepressants, antiepileptics,
and opioids. These medications are limited in their eﬀective-
ness, they have considerable side eﬀects, and they have no
eﬀect on the processes by which hyperglycaemia leads to cell
damage [5]. Antioxidants, such as alpha lipoic acid, could
theoretically be eﬀective in treating diabetic neuropathy. In2 International Journal of Endocrinology
Table 1: Methodological quality assessment of the included intervention studies.
Ziegler 1995 [15]
ALADIN
Ruhnau 1999 [16]
ORPIL
Ametov 2003 [17]
SYDNEY
Ziegler 2006 [18]
SYDNEY 2
(1) Randomisation? yes yes yes yes
(2) Concealment of allocation? yes yes yes yes
(3) Patients blinded? yes yes yes yes
(4) Doctors blinded? yes yes yes yes
( 5 ) I n v e s t i g a t o r s b l i n d e d ? N ON ON ON O
(6) Groups comparable at
baseline? yes yes yes yes
(7) Follow-up complete of
>80% of patients? yes yes yes yes
(8) Intention-to-treat analysis? yes yes yes yes
Level of evidence 1b 1b 1b 1b
1951, alpha lipoic acid was identiﬁed as a coenzyme in
the tricarboxylic acid cycle (Krebs Cycle) [6]. Alpha lipoic
acid is also a potent antioxidant, reported to reduce and
prevent diabetic micro- and macrovascular complications in
animal models [7, 8]. A recent study in humans with type
1 diabetes mellitus showed a normalisation of the increased
AGE formation and a reduction of the hexosamine pathway
[9]. By preventing the damage caused by hyperglycaemia,
alpha lipoic acid may not only be an analgesic treatment
but may also improve nerve function. In addition, recent
evidence shows that alpha lipoic acid decreases neuronal
sensitivity to pain by selectively inhibiting neuronal T-
type calcium channels [10]. Moreover, compared to the
medications currently in use, alpha lipoic acid has few side
eﬀects [11]. In Germany, alpha lipoic acid is approved for the
treatmentofdiabeticneuropathicpainandcoveredbyhealth
insurance companies, but use has not been widely adopted
elsewhere.
An earlier meta-analysis of four randomized controlled
trials (RCTs) on alpha lipoic acid (600mg/day) in patients
with diabetes and neuropathic pain concluded that three
weeks of treatment with intravenous alpha lipoic acid (600
mg/day) led to a signiﬁcant decrease in reported neuropathic
pain [12]. However, studies investigating the eﬀect of oral
administration were not included. In addition, the meta-
analysis did not fulﬁl the Cochrane methodological criteria
for systematic reviews. A protocol for a proposed systematic
review can be found in the Cochrane Library [13]. Recently,
we performed a qualitative systematic review of the literature
[14]. In addition, it was our purpose to extend the literature
search and to perform a quantitative meta-analysis. The
aim of this meta-analysis was to evaluate the eﬀects of
intravenous as well as oral administration of alpha lipoic
acid versus placebo in patients with symptomatic peripheral
diabetic neuropathy.
2.Research DesignandMethods
2.1. Literature Search. In November 2010, three of the au-
thors (GSM, AA, and NK) conducted a search for relevant
publications in the electronic database MEDLINE, using the
search engine PubMed, and EMBASE. The search strategy
used in MEDLINE used the terms “lipoic acid”, “thioctic
acid”, and “diabet∗” and the MeSH terms “thioctic acid”
and “diabetes mellitus”: (((lipoic acid OR thioctic acid OR
thioctic acid [MeSH]) AND (diabete∗ OR diabeti∗ OR
diabeto∗ OR diabetes mellitus [MeSH])) AND ((clinical
[Title/Abstract] AND trial [Title/Abstract]) OR clinical
trials [MeSH Terms] OR clinical trial [Publication Type]
OR random∗[Title/Abstract] OR random allocation [MeSH
Terms] OR therapeutic use [MeSH Subheading])). A similar
search strategy was used in EMBASE: ((lipoic acid OR
thioctic acid) AND (diabetes mellitus OR diabetic∗)A N D
([cochrane review]/lim OR [controlled clinical trial]/lim OR
[meta analysis]/lim OR [randomized controlled trial]/lim
OR [systematic review]/lim)). All authors obtained the same
results.
2.2. Study Selection. For study selection, the following inclu-
sion criteria were used: (1) RCTs on alpha lipoic acid, (2) a
studypopulationconsistingofpatientswithdiabetesmellitus
and peripheral neuropathic pain, and (3) use of the total
symptomscore(TSS)astheoutcomemeasure.Languagewas
not arestriction. GSM,AA,andNK independentlyidentiﬁed
studies to be included in the review by checking the titles
and abstracts downloaded from the databases. A consensus
meetingwasthenheldtoresolveanydisagreements.Theﬁnal
decision to include or exclude any study was based on the
article’s full text. The reference lists of the identiﬁed studies
were reviewed to discover additional potentially eligible
studies. Unpublished data and conference proceedings were
excluded from this review.
2.3. Methodologic Quality Assessment. The aforementioned
authors proceeded to independently evaluate the quality of
each study using the standardised evaluation form for RCTs
and systematic reviews developed by the Dutch Cochrane
Centre (http://www.cochrane.nl/)( Table 1). Levels of evi-
dence and recommendation grades were applied according
to the Oxford Centre of Evidence-based Medicine, version
2001 (http://www.cebm.net/index.aspx?o=1025/).International Journal of Endocrinology 3
Table 2: Total Symptom Score (TSS): scoring system for neu-
ropathic symptoms (pain, burning, paresthesia, and numbness).
The score can range from 0 (no symptoms) to maximally 14.64
(all symptoms present, severe, continuous).
Symptom frequency Symptom intensity
Absent Slight Moderate Severe
Occasional 0 1.00 2.00 3.00
Frequent 0 1.33 2.33 3.33
(Almost) continuous 0 1.66 2.66 3.66
2.4. Outcome Measure. The primary outcome measure in
this meta-analysis was the total symptom score (TSS). The
TSS is a questionnaire in which the patient is asked to
assess the intensity (absent, mild, moderate, severe) and
the frequency (now and then, often, continuous) of four
symptoms (pain, burning, paresthesia, numbness) resulting
in a scaled score in which 0 means no symptoms and 14.64
means that all four symptoms are severe and more or less
continuously present (Table 2). A 30% change on this scale is
considered to be clinically relevant (or ≥2 points in patients
with a starting score ≤4 points) [15].
2.5. Statistical Analysis. For the purpose of this meta-anal-
ysis, overall results based on TSS scores were combined for
oral and intravenous administration of alpha lipoic acid
and placebo. Meta-analysis was undertaken using RevMan5
software (The Nordic Cochrane Centre, The Cochrane
Collaboration). The I2 statistic was used to assess statistical
heterogeneity [19]. An I2 > 30% was considered to denote
heterogeneity. A random-eﬀect model was used in case of
heterogeneity, a ﬁxed-eﬀect model in the absence of hetero-
geneity. The inverse-variance method was used to weigh the
scores of individual studies. When possible, study authors
were contacted to clarify data. Studies were excluded from
the meta-analysis if insuﬃcient information was provided
to enable standard error calculation. The Mantel–Haenszel
method was subsequently applied to estimate pooled eﬀect
sizes. In order to explore the robustness of our results
we conducted the following, a priori speciﬁed, subgroup
analyses: intravenous and oral administration of alpha lipoic
acid versus placebo.
We adhered to the QUOROM guidelines for the report-
ing of meta-analyses of randomised trials [20].
3. Results
3.1. Identiﬁcation andSelection of Studies. The searchyielded
242 publications in Medline and 112 in Embase (Figure 1).
The 112 publications found in Embase were also identiﬁed
in Medline. After reviewing the titles and the abstracts of the
242publications,10randomisedplacebo-controlledtrialson
alpha lipoic acid in patients with diabetic neuropathic pain
were selected [15–18, 21–26]. After reading the complete
articles, two studies were excluded [21, 22], because they
dealt with the eﬀects of alpha lipoic acid on autonomic
instead of diabetic neuropathy. Two studies [23, 24]w e r e
excluded because the TSS was not used as an outcome
measure. There was no disagreement among the reviewers
regarding the studies selected for inclusion.
3.2. Methodological Quality Assessment. A survey of the me-
thodological quality assessment is shown in Table 1.F o u r
of the RCTs [15–18] were of good methodological quality
(level1b).TwoRCTs[25,26]hadsubstantialmethodological
limitations (level 2b). The study of Liu et al. [26]w a s
excluded from our meta-analysis because of unacceptable
methodological limitations, including absence of allocation
concealment and blinding. The study of Ziegler et al.
[25] was considered for inclusion despite exclusion bias
due to selective loss to follow-up, but the article provided
insuﬃcientinformationtoenablestandarderrorcalculation.
Thestudyauthorswerecontactedtoclarifydata,buttheydid
not respond to repeated requests. Therefore, also this study
was excluded from the meta-analysis.
3.3. Descriptive Analyses of Selected Randomized Controlled
Trials. Finally, four RCTs were included in our systematic
review and meta-analysis. The study populations in the four
selected RCTs were all made up of patients with peripheral
diabetic neuropathy [15–18] .T h ea g er a n g ew a sf r o m1 8
to 74 years, and most of the patients included had type 2
diabetes mellitus. The eﬀects of orally administered alpha
lipoic acid were investigated in two studies and intravenous
administration in another two studies (Table 3). Two studies
incorporated multiple dose comparisons. The dosage of
alpha lipoic acid ranged from 100 to 1800mg per day.
Intravenous alpha lipoic acid was given for three weeks, and
oral administration varied between three weeks and six
months.
AsigniﬁcantimprovementintheTSSscoreswasreported
in all studies. In these studies an average 50% reduction was
seen in the TSS with the oral or intravenous administration
of at least 600mg per day. However, when compared to the
subjects in the control groups, the reduction in TSS was
actually less than the clinically relevant threshold of 30%
[15], as the TSS in the control group also decreased. This
wasparticularlyevidentinthestudieswherealphalipoicacid
was administered orally. In one study, in which the alpha
lipoic acid was administered intravenously, the intervention
group did show a more than 30% reduction in TSS when
compared to the control group [16]. Dosages higher than
600mg per day did not result in a further improvement in
the TSS and resulted in a greater incidence of side eﬀects
such as nausea, vomiting, and dizziness. The side eﬀects
seen with dosages ≤600mg per day were not diﬀerent than
seen with placebo. A safety analysis of treatment with alpha
lipoic acid over 4 years in diabetic polyneuropathy [27]
showed that treatment tolerability and discontinuations due
to lack of tolerability did not diﬀer between placebo and
treatment groups. However, the rates of serious adverse
events were higher on alpha lipoic acid (38.1%) than those
on placebo (28.0%) [27]. Of all reported adverse events, only
heart rate and rhythm disorders were observed signiﬁcantly
more frequently in patients treated with alpha lipoic acid
compared to patient treated with placebo (6.9% versus 2.7%,
P 0.047) [27].4 International Journal of Endocrinology
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2 studies were excluded because of
methodological limitations 
6 RCTs were included
232 studies were excluded on screening 
abstracts and titles for inclusion criteria
to meet the inclusion criteria 
242 potentially relevant studies were 
identiﬁed and screened for retrieval
10 studies were retrieved for more 
detailed application of inclusion criteria 
4 studies were excluded due to failure
4 studies were included for meta-analysis;
2 studies on intravenous administration 
and 2 on oral administration 
[15–18, 21–26]
[21–24]
[15, 16–18, 25, 26]
[25, 26]
[15, 17]
[16, 18]
Figure 1: Flow diagram.
3.4. Meta-Analysis. Overall, the pooled standardized mean
diﬀerence estimated from all trials revealed a reduction in
TSS scores of −2.26 (CI: −3.12 to −1.41; P = 0.00001)
in favour of alpha lipoic acid administration (Table 4). The
outcome of the subgroup analyses of oral administration
(−1.78 CI: −2.45 to −1.10; P = 0.00001) and intravenous
administration (−2.81 CI: −4.16 to −1.46; P = 0.0001)
conﬁrmed the robustness of the overall result (Tables 5 and
6).
4. Discussion
Based on the four level 1b randomized, placebo-controlled
studies included here, there is evidence to support that
alpha lipoic acid causes a signiﬁcant and clinically relevant
decrease in neuropathic pain when administered for a period
of three weeks at a dosage of 600mg per day (grade of
recommendationA).However,thesigniﬁcantimprovements
seen after the oral administration of alpha lipoic acid over
a period of 3–5 weeks at a dosage of ≥600mg per day are
probablynotclinicallyrelevant,becausethereductioninTSS
was actually less than the threshold of 30% considered to be
clinically relevant. There are, at present, no publications in
which the eﬀects of long-term treatment with intravenous or
oral lipoic acid are presented.
The RCTs are primarily performed by a single German
research group. A number of these studies were multicenter
studies which included German as well as Russian, Israeli,
and Croatian patients. Presumably, there is no overlap
between these patient populations. All studies were spon-
sored by a pharmaceutical company which manufactured
alpha lipoic acid. A number of the authors received salaries
from this company, besides which, the pharmaceutical com-
panyalsohadrepresentativessitting ontheadvisorybodyfor
several of these studies.
Itisstrikingthatclinicallyrelevanteﬀectsonneuropathic
painareseenafteronly3–5weeksofalphalipoicacidadmin-
istration. This is unexpectedly rapid for an antioxidising
diet supplement. This may be explained by the selective
modulation of neuronal T-type calcium channels by alpha
lipoic acid [10]. In studies on diabetic autonomic neuropa-
thy, eﬀects of alpha lipoic acid were seen after 8–16 weeks
[21, 22], depending on the study design.6 International Journal of Endocrinology
Table 4: Standardized mean diﬀerences for the administration of orally and intravenously administered alpha-lipoic acid versus placebo in
the treatment of neuropathic pain. Diamond denotes pooled estimate of overall eﬀect. Weighing of individual studies is based on the inverse
variance method. For subgroups, see Table 3.
Study or subgroup
Ametov et al. 2003
Ruhnau et al. 1999
Ziegler et al.1995b
Ziegler et al. 1995c
Ziegler et al. 2006a
Ziegler et al. 2006b
Ziegler et al. 2006c
Total (95% CI)
Mean SD
1.53
1.88
4.1
3.7
3.03
3.28
3.54
Total
60
12
63
66
45
47
46
339
Mean SD
1.97
1.5
3.2
3.2
3.18
3.18
3.18
Total
60
12
66
66
43
43
43
333
Weight
18.1%
13.3%
13.9%
14.5%
13.7%
13.5%
13.1%
100%
IV, random, 95% CI
Alpha-lipoic acid Placebo Mean difference Mean difference
IV, random, 95% CI
0 2 4
Favours alpha-lipoid acid Favours placebo
−5.72
−3.75
−5
−4.5
−4
−4.85
−4.5
−4.7
−1.83
−1.94
−2.6
−2
−2.6
−2.92
−2.92
−2.92
−3.89 (−4.52, −3.26)
−1.81 (−3.17, −0.45)
−2.40 (−3.67, −1.13)
−1.90 (−3.08, −0.72)
−1.93 (−3.23, −0.63)
−1.58 (−2.92, −0.24)
−1.78 (−3.18, −0.38)
−2.26 (−3.12, −1.41)
Test for over all eﬀect: Z = 5.19 ( )
Heterogeneity: τ2 = 0.95; χ2 = 22.98, df = P = 0.0008); I2 = 74% 6 (
0.00001
Table 5: Standardized mean diﬀerences for the administration of intravenously administered alpha-lipoic acid versus placebo in the
treatment of neuropathic pain. Diamond denotes pooled estimate of overall eﬀect. Weighing of individual studies is based on the inverse
variance method. For subgroups, see Table 3.
Favours alpha-lipoid acid Favours placebo
Study or subgroup
Ametov et al. 2003
Ziegler et al. 1995b
Ziegler et al. 1995c
Total (95% CI)
Mean SD
1.53
4.1
3.7
Total
60
63
66
189
Mean SD
1.97
3.2
3.2
Total
60
66
66
192
Weight
38.1%
30.4%
31.6%
100%
IV, random, 95% CI
Alpha-lipoic acid Placebo Mean difference Mean difference
IV, random, 95% CI
−5.72
−5
−4.5
−1.83
−2.6
−2.6
−3.89 (−4.52, −3.26)
−2.40 (−3.67, −1.13)
−1.90 (−3.08, −0.72)
−2.81 (−4.16, −1.46)
Test for over all eﬀect: Z = 4.07 ( 0.0001)
Heterogeneity: τ2 = 1.14; χ2 = 10.68, df = 2 (P = 0.005); I2 = 81% 024 −4 −2
Table 6: Standardized mean diﬀerences for the administration of orally administered alpha-lipoic acid versus placebo in the treatment of
neuropathicpain.Diamonddenotespooledestimateofoveralleﬀect.Weighingofindividualstudiesisbasedontheinversevariancemethod.
For subgroups, see Table 3.
Study or subgroup
Ruhnau et al. 1999
Ziegler et al. 2006a
Ziegler et al. 2006b
Ziegler et al. 2006c
Total (95% CI)
Heterogeneity: χ2 = 0.14, df = 3 (P = 0.99); I² = 0%
Mean SD
1.88
3.03
3.28
3.54
Total
12
45
47
46
150
Mean
−1.94
−2.92
−2.92
−2.92
SD
1.5
3.18
3.18
3.18
Total
12
43
43
43
141
Weight
24.5%
26.9%
25.4%
23.2%
100.0%
IV, ﬁxed, 95% CI
−1.81 (−3.17, −0.45)
−1.93 (−3.23, −0.63)
−1.58 (−2.92, −0.24)
−1.78 (−3.18, −0.38)
−1.78 (−2.45, −1.10)
Alpha-lipoic acid Placebo Mean difference Mean difference
IV, ﬁxed, 95% CI
Favours alpha-lipoid acid Favours placebo
−3.75
−4.85
−4.5
−4.7
024 −4 −2
The included RCTs were not designed for neuropathic
pain. Individual scores on each of the four symptoms of
the TSS (pain, burning, paresthesia, numbness) were not
available from the included studies.
Unfortunately, there are not yet any results published for
its administration over a longer time period. The continued,
long-term eﬀectiveness of any treatment is of the utmost
importance for chronic conditions such as diabetic neuropa-
thy.
In The Netherlands, the cost of using alpha lipoic acid
at a dosage of 600mg per day varies between 17.15 and
75.00eurospermonth,dependingonthemanufacturer[14].
In comparison, the costs of amitriptyline, carbamazepine,
duloxetine, gabapentin, and pregabalin are, respectively,
3.41, 9.38, 35.80, 53.75, and 71.71 euros per month (based
on the Z-index tax, 2010) [28].
Finally,ameta-analysisislikelytosuﬀerfrompublication
bias,methodologicaldeﬁciencies,andheterogeneity.WekeptInternational Journal of Endocrinology 7
the likelihood of bias to a minimum by developing a detailed
protocol before starting this study, undertaking a meticulous
search for published studies, and using explicit methods for
study selection, data extraction, and data analysis. Also, we
studied the totality of the randomized evidence by including
all relevant properly randomized trials.
We conclude that intravenous administration of alpha
lipoic acid leads to signiﬁcant and clinically relevant im-
provements of symptomatic peripheral diabetic neuropathy
in the short term. The results we present are encouraging
enough to consider intravenous alpha lipoic acid for the
treatment of diabetic neuropathy in patients, who do not
respond to common therapy. It is unclear if the signiﬁcant
improvements seen with the oral administration of alpha
lipoic acid are clinically relevant. Additional research of
longer duration using an informative neuropathic pain scale
will be necessary to investigate the eﬀects of both routes.
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